Welcome!

News Feed Item

Intrexon Announces Second Quarter and First Half 2014 Financial Results

GERMANTOWN, Md., Aug. 14, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its second quarter and first half results for 2014. 

Business Highlights and Recent Developments:

  • Acquired Trans Ova Genetics, L.C. ("Trans Ova"), an industry-leading provider of bovine reproductive technologies and the largest producer and supplier of bovine embryos in the United States. The combined technologies of Intrexon and Trans Ova should enable a leadership position in bovine genetics to accelerate efficiency in related food and protein production.
  • Achieved, through Intrexon's Methane Bioconversion platform, the production of farnesene, a key building block chemical for diesel fuel, lubricants and specialty products. Farnesene is the second product, following isobutanol, which Intrexon has upgraded from natural gas by employing its unique cellular engineering capabilities.
  • Enhanced the collaboration with a global animal health company to enable remote access to Intrexon's suite of technologies via the groundbreaking BeyondBio™ platform. The BeyondBio™ platform combines the principles of precision engineering, statistical modeling, automation, and lean production to power the next generation of optimized biological designs for unique DNA-based solutions across broad markets.
  • Announced an expansion of immuno-oncology programs, in conjunction with ZIOPHARM Oncology, an Exclusive Channel Collaboration (ECC) partner, to include chimeric antigen receptor T-cell (CAR-T) therapy and increased applications of the RheoSwitch® platform and its unique capabilities into targeted cellular oncology products.
  • Fibrocell Science, facilitated by its ECC with Intrexon, received Orphan Drug Designation for genetically-modified autologous human fibroblasts that combine its autologous fibroblast technology with Intrexon's UltraVector® synthetic biology platform to treat Recessive Dystrophic Epidermolysis (RDEB), a devastatingly debilitating, genetic disease that causes severe blistering and areas of missing skin.

Second Quarter Financial Highlights:

  • Total revenues of $11.8 million, an increase of 76% over the second quarter of 2013;
  • Net loss of $52.0 million, including noncash charges of $43.0 million, attributable to Intrexon, or ($0.53) per share;
  • Adjusted EBITDA of $(10.4) million, or $(0.11) per share; and
  • Cash consideration received for research and development services covered 49% of cash operating expenses (exclusive of operating expenses of majority-owned consolidated subsidiaries).

First Half Financial Highlights:

  • Total revenues of $19.6 million, an increase of 86% over the first half of 2013;
  • Net loss of $47.9 million, including noncash charges of $27.1 million, attributable to Intrexon, or ($0.49) per share;
  • Adjusted EBITDA of $7.2 million, or $0.07 per share; and
  • Total consideration received for technology access fees and reimbursement of research and development expenses covered 130% of cash operating expenses (exclusive of operating expenses of majority-owned consolidated subsidiaries).

"Year to date, cash consideration from our channel collaborators has been more than sufficient to pay our cash operating expenses, while we have continued to build value in our portfolio of royalties and profits participation across multiple product candidates in development across various industries," commented Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon.  "The primary benefit of the attainment of this goal, one we have been working toward for several years, is that shareholder capital is preserved while our portfolio of backend economics in what we expect to be ultimately commercialized products continues to advance.  Considering our present deal queue, including advanced-stage negotiations with new partners, we anticipate building on this trend throughout the balance of 2014."

Second Quarter 2014 Financial Results Compared to Prior Year Period

Total revenues were $11.8 million for the quarter ended June 30, 2014 compared to $6.7 million for the quarter ended June 30, 2013, an increase of $5.1 million, or 76 percent.  The $5.1 million increase in collaboration revenue resulted primarily from the following: (i) recognition of deferred revenue for upfront payments received from 11 collaborations or expansions thereof signed by Intrexon between July 1, 2013 and June 30, 2014; (ii) recognition of research and development services performed by the Company pursuant to these new collaborations; and (iii) increased research and development services performed by Intrexon for collaborations in effect prior to June 30, 2013 as a result of the progression of current programs and the initiation of new programs with these collaborators. 

Research and development expenses were $14.5 million for the quarter ended June 30, 2014 compared to $13.5 million for the quarter ended June 30, 2013.  The $1.0 million increase in research and development expenses is primarily the result of a $1.5 million increase in compensation costs due to stock options grants Intrexon made to research and development employees in the first quarter of 2014.  Lab supplies expense increased $0.6 million due to the increased level of research and development services provided to the Company's collaborators.  These increases were offset by a $1.0 million decrease in third party technology license fees due to the termination of a licensing agreement.

General and administrative expenses were $15.4 million for the quarter ended June 30, 2014 compared to $7.4 million for the quarter ended June 30, 2013.  The $8.0 million increase in general and administrative expenses is primarily the result of $6.0 million of additional compensation costs resulting from Intrexon's hiring of additional employees in order to effectively operate as a public company and also from stock option grants Intrexon made to general and administrative employees in the first quarter of 2014.  The Company's legal and professional fees increased $1.3 million due to increased costs to operate as a public company and also various merger and acquisition and other business development activities.

Total other income (expense) includes the unrealized changes in the fair value of equity securities Intrexon holds in its collaborators which depreciated $(33.8) million for the quarter ended June 30, 2014 compared to appreciation of $7.7 million for the quarter ended June 30, 2013.

First Half 2014 Financial Results Compared to Prior Year Period

Total revenues were $19.6 million for the six months ended June 30, 2014 compared to $10.6 million for the six months ended June 30, 2013, an increase of $9.0 million, or 86 percent.  The $9.0 million increase in collaboration revenue resulted primarily from the following:  (i) recognition of deferred revenue for upfront payments received from 11 collaborations or expansions thereof signed by Intrexon between July 1, 2013 and June 30, 2014; (ii) recognition of research and development services performed by the Company pursuant to these new collaborations; and (iii) increased research and development services performed by Intrexon for collaborations in effect prior to June 30, 2013 as a result of the progression of current programs and the initiation of new programs with these collaborators. 

Research and development expenses were $26.6 million for the six months ended June 30, 2014 compared to $24.9 million for the six months ended June 30, 2013.  The $1.7 million increase in research and development expenses is primarily the result of a $1.3 million increase in compensation costs due to stock options grants Intrexon made to research and development employees in the first quarter of 2014 and the inclusion of six months of salaries, benefits and other personnel costs for AquaBounty Technologies, Inc. ("AquaBounty") in Intrexon's consolidated results for 2014 compared to approximately three and a half months in 2013.  Other AquaBounty research and development expenses increased $0.5 million for this same reason.  These increases were offset by a $1.0 million decrease in third party technology license fees due to the termination of a licensing agreement.

General and administrative expenses were $29.0 million for the six months ended June 30, 2014 compared to $13.9 million for the six months ended June 30, 2013.  The $15.1 million increase in general and administrative expenses is primarily the result of $8.9 million of additional compensation costs resulting from Intrexon's hiring of additional employees in order to effectively operate as a public company, stock option grants the Company made to general and administrative employees in the first quarter of 2014, and inclusion of six months of costs for AquaBounty employees in 2014 compared to approximately three and a half months in 2013.  The Company also incurred stock-based compensation expense for options granted to its non-employee directors, which increased $1.8 million due to changes in its director compensation plan, which Intrexon adopted in conjunction with its becoming a public company.  Intrexon's legal and professional fees increased $2.9 million due to increased costs to operate as a public company, the formation of its joint venture with Intrexon Energy Partners and various merger and acquisition and other business development activities.

Total other income (expense) includes the unrealized changes in the fair value of equity securities Intrexon holds in its collaborators which depreciated $(11.9) million for the six months ended June 30, 2014 compared to $(21.6) million for the six months ended June 30, 2013. Total other income (expense), net for the six months ended June 30, 2013 includes a $7.4 million gain on the Company's previously held equity interest in AquaBounty as a result of its consolidating AquaBounty as of March 15, 2013.

Trans Ova Acquisition Details

Effective August 8, 2014, Intrexon closed the above-referenced acquisition of Trans Ova.  Total consideration paid at closing consisted of $60.0 million in cash and the issuance of 1,444,388 shares of Intrexon common stock.  Intrexon is obligated to pay an additional $20.0 million in cash in equal installments on the first, second and third anniversaries of closing and may be obligated to make other contingent payments as specified in the purchase agreement.  For the year ended December 31, 2013, net sales of Trans Ova were $63.2 million, which represented an increase of $15.0 million, or 30 percent, over 2012 net sales.  For the year ended December 31, 2013, net income of Trans Ova was $4.4 million

Conference Call and Webcast

The Company will host a conference call today at 5:30pm ET to discuss the second quarter and first half 2014 financial results and provide a general business update.  The conference call may be accessed by dialing 1-877-870-4263 (Domestic US) and 1-412-317-0790 (International) and asking to join the "Intrexon Conference Call."  Participants may also access the live webcast through Intrexon's website in the Investors section under Calendar of Events.

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create biologically-based products that improve the quality of life and the health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems.  The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells.  We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.dna.com.

Non-GAAP Financial Measures

This press release presents Adjusted EBITDA and Pro Forma Adjusted EBITDA earnings per share, which are non-GAAP financial measures within the meaning of applicable rules and regulations of the Securities and Exchange Commission ("SEC"). For a reconciliation of Adjusted EBITDA to net loss attributable to Intrexon in accordance with generally accepted accounting principles and for a discussion of the reasons why the company believes that these non-GAAP financial measures provide information that is useful to investors see the tables below under "Reconciliation of GAAP to Non-GAAP Measures."  Such information is provided as additional information, not as an alternative to Intrexon's consolidated financial statements presented in accordance with GAAP, and is intended to enhance an overall understanding of the Company's current financial performance.

Trademarks

Intrexon, BeyondBio, UltraVector, RheoSwitch Therapeutic System, RheoSwitch, RTS, and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are based upon Intrexon's current expectations and projections about future events and generally relate to Intrexon's plans, objectives and expectations for the development of Intrexon's business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. These risks and uncertainties include, but are not limited to, (i) Intrexon's current and future ECCs and joint ventures; (ii) developments concerning Intrexon's collaborators; (iii) Intrexon's ability to successfully enter new markets or develop additional products, whether with its collaborators or independently; (iv) competition from existing technologies and products or new technologies and products that may emerge; (v) actual or anticipated variations in Intrexon's operating results; (vi) actual or anticipated fluctuations in Intrexon's competitors' or its collaborators' operating results or changes in their respective growth rates; (vii) Intrexon's cash position; (viii) market conditions in Intrexon's industry; (ix) Intrexon's ability, and the ability of its collaborators, to protect Intrexon's intellectual property and other proprietary rights and technologies; (x) Intrexon's ability, and the ability of its collaborators, to adapt to changes in laws or regulations and policies; (xi) the ability of Intrexon's collaborators to secure any necessary regulatory approvals to commercialize any products developed under the ECCs; (xii) the rate and degree of market acceptance of any products developed by a collaborator under an ECC; (xiii) Intrexon's ability to retain and recruit key personnel; (xiv) Intrexon's expectations related to the use of proceeds from its initial public offering; (xv) Intrexon's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and (xvi) Intrexon's expectations relating to Trans Ova, AquaBounty and any other consolidated subsidiaries. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Intrexon's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Intrexon's Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intrexon's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intrexon undertakes no duty to update this information unless required by law.

For more information regarding Intrexon Corporation, contact:

Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
[email protected]

Corporate Contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
[email protected]


 


 

Intrexon Corporation and Subsidiaries

Consolidated Balance Sheets

(Unaudited)

 

















(Amounts in thousands)


June 30, 2014



December 31, 2013

Assets








Current assets








Cash and cash equivalents


$

74,505



$

49,509

Short-term investments



101,046




127,980

Receivables








Trade



806




790

Related parties



8,304




5,285

Other



698




1,282

Prepaid expenses and other



2,944




2,710









Total current assets



188,303




187,556

Long-term investments



73,545




60,581

Equity securities



134,895




141,525

Property, plant and equipment, net



17,389




16,629

Intangible assets, net



45,406




41,956

Goodwill



34,865




13,823

Investments in affiliates



4,997




6,284

Other assets



1,137




1,118









Total assets


$

500,537



$

469,472













Liabilities and Total Equity












Current liabilities








Accounts payable


$

1,799



$

1,057

Accrued compensation and benefits



4,094




5,157

Other accrued liabilities



3,998




4,217

Deferred revenue



10,706




7,793

Related party payables



95




1,605









Total current liabilities



20,692




19,829

Long term debt



2,001




1,653

Deferred revenue



88,747




65,778

Other long term liabilities



731




869









Total liabilities



112,171




88,129









Commitments and contingencies








Total equity








Common stock






Additional paid-in capital



797,516




743,084

Accumulated deficit



(424,342)




(376,414)

Accumulated other comprehensive income



81




52









Total Intrexon shareholders' equity



373,255




366,722

Noncontrolling interests



15,111




14,621









Total equity



388,366




381,343









Total liabilities and total equity


$

500,537



$

469,472

 


Intrexon Corporation and Subsidiaries

Consolidated Statements of Operations

(Unaudited)




























Three months ended


Six months ended

(Amounts in thousands, except share
and per share data)

June 30,


June 30,



2014



2013



2014



2013













Revenues












Collaboration revenues

$

11,764


$

6,674


$

19,601


$

10,538

Other revenues


23



16



40



37

Total revenues


11,787



6,690



19,641



10,575













Operating Expenses












Research and development


14,479



13,510



26,570



24,921

General and administrative


15,390



7,434



29,025



13,914

Total operating expenses


29,869



20,944



55,595



38,835

Operating loss


(18,082)



(14,254)



(35,954)



(28,260)













Other Income (Expense)












Unrealized appreciation (depreciation) in fair value of equity securities


(33,777)



7,734



(11,855)



(21,635)

Gain on previously held equity investment








7,415

Interest expense


(40)



(11)



(79)



(25)

Investment income


110



15



198



20

Other expense


(74)



(3)



(82)



(6)

Total other income (expense)


(33,781)



7,735



(11,818)



(14,231)

Equity in net loss of affiliates


(1,355)





(1,891)



(390)

Loss before tax


(53,218)



(6,519)



(49,663)



(42,881)

Income tax benefit (expense)


283





(23)



Net loss

$

(52,935)


$

(6,519)


$

(49,686)


$

(42,881)

Net loss attributable to the noncontrolling interests


892



556



1,758



607

Net loss attributable to Intrexon

$

(52,043)


$

(5,963)


$

(47,928)


$

(42,274)

Accretion of dividends on redeemable convertible preferred stock




(7,942)





(14,347)

Net loss attributable to common shareholders

$

(52,043)


$

(13,905)


$

(47,928)


$

(56,621)

Net loss attributable to common shareholders per share, basic and diluted

$

(0.53)


$

(2.45)


$

(0.49)


$

(10.00)

Weighted average shares outstanding, basic and diluted


98,892,601



5,667,557



98,113,493



5,664,665













 

Intrexon Corporation and Subsidiaries
Reconciliation of GAAP to Non-GAAP Measures 
(Unaudited)

Adjusted EBITDA. To supplement Intrexon's financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), Intrexon presents Adjusted EBITDA.  A reconciliation of Adjusted EBITDA to Intrexon's net income or loss attributable to Intrexon under GAAP appears below.  Adjusted EBITDA is a non-GAAP financial measure that Intrexon calculates as net income or loss attributable to Intrexon adjusted for income tax expense or benefit, interest expense, depreciation and amortization, stock-based compensation, contribution of services by shareholder, unrealized appreciation or depreciation in the fair value of equity securities, gain on previously held equity investment, equity in net loss of affiliate and the change in deferred revenue related to upfront and milestone payments.  Adjusted EBITDA is a key metric for Intrexon's management and Board of Directors for evaluating the Company's financial and operating performance, generating future operating plans and making strategic decisions about the allocation of capital.  Management and the Board of Directors believe that adjusted EBITDA is useful to understand the long-term performance of Intrexon's core business and facilitates comparisons of the Company's operating results over multiple reporting periods.  Intrexon is providing this information to investors and others to assist them in understanding and evaluating the Company's operating results in the same manner as its management and board of directors. While Intrexon believes that this non-GAAP financial measure is useful in evaluating its business, and may be of use to investors, this information should be considered as supplemental in nature and is not meant as a substitute for the related financial information prepared in accordance with GAAP. In addition, this non-GAAP financial measure may not be the same as non-GAAP financial measures presented by other companies.  Adjusted EBITDA is not a measure of financial performance under GAAP, and is not intended to represent cash flows from operations under GAAP and should not be used as an alternative to net income or loss as an indicator of operating performance or to represent cash flows from operating, investing or financing activities as a measure of liquidity.  Intrexon compensates for the limitations of Adjusted EBITDA by using it only to supplement the Company's GAAP results to provide a more complete understanding of the factors and trends affecting the Company's business.  Adjusted EBITDA has its limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of Intrexon's results as reported under GAAP.

In addition to the reasons stated above, which are generally applicable to each of the items Intrexon excludes from its non-GAAP financial measure, Intrexon believes it is appropriate to exclude certain items for the following reasons:

  • Interest expense may be subject to changes in interest rates which are beyond Intrexon's control;
  • Depreciation of Intrexon's property and equipment and amortization of acquired identifiable intangibles can be affected by the timing and magnitude of business combinations and capital asset purchases;
  • Stock-based compensation expense is a noncash expense and may vary significantly based on the timing, size and nature of awards granted and also because the value is determined using formulas which incorporate variables, such as market volatility;
  • Contribution of services by shareholder is a noncash expense which Intrexon excludes in evaluating its financial and operating performance;
  • Unrealized appreciation or depreciation in the fair value of securities which Intrexon holds in its collaborators may be significantly impacted by market volatility and other factors which are outside of the Company's control in the short term and Intrexon intends to hold these securities over the long term;
  • Equity in net loss of affiliate reflects Intrexon's proportionate share of the income or loss of entities over which the Company has significant influence, but not control, and accounts for using the equity method of accounting. Gain on previously held equity investment occurred as a result of a step acquisition of AquaBounty Technologies, Inc. which was completed in the first quarter of 2013 which resulted in a controlling interest by Intrexon and the consolidation of the investment. Intrexon believes excluding the impact of such losses or gains on these types of strategic investments from its operating results is important to facilitate comparisons between periods; and
  • GAAP requires Intrexon to account for its collaborations as multiple-element arrangements. As a result, the Company defers certain collaboration revenues because certain of its performance obligations cannot be separated and must be accounted for as one unit of accounting. The collaboration revenues that Intrexon so defers arise from upfront and milestone payments received from the Company's collaborators, which Intrexon recognizes over the future performance period even though the Company's right to such consideration is neither contingent on the results of Intrexon's future performance nor refundable in the event of nonperformance. In order to evaluate Intrexon's operating performance, its management adjusts for the impact of the change in deferred revenue for these upfront and milestone payments in order to include them as a part of adjusted EBITDA when the transaction is initially recorded. The adjustment for the change in deferred revenue removes the noncash revenue recognized during the period and includes the cash and stock received from collaborators for upfront and milestone payments during the period. Intrexon believes that adjusting for the impact of the change in deferred revenue in this manner is important since it permits the Company to make quarterly and annual comparisons of the Company's ability to consummate new collaborations or to achieve significant milestones with existing collaborators. Further, Intrexon believes it is useful when evaluating its financial and operating performance, generating future operating plans and making strategic decisions about the allocation of capital.

Pro forma adjusted EBITDA per share.  Intrexon's calculations for pro forma adjusted EBITDA per share, basic and diluted, assumes, as of the end of the respective period, the conversion of all outstanding shares of Intrexon's redeemable convertible preferred stock plus all cumulative dividends payable thereon into shares of common stock as if such conversion had occurred as of the later of (i) the beginning of the period or (ii) the issuance date of those shares.  Because all of Intrexon's shares of redeemable convertible preferred stock and all accrued and cumulative dividends thereon automatically converted into common shares upon the closing of the Company's initial public offering on August 13, 2013, Intrexon believes that the inclusion of such shares on an as-converted basis results in a useful metric for its investors, analysts and others when evaluating Intrexon's results on a comparable basis with other periods.  While Intrexon's management and board of directors believe that this non-GAAP per share metric is useful in evaluating the Company's past adjusted EBITDA results, and may be of use to investors, analysts and others, this information should be considered supplemental in nature and is not meant as a substitute for the per share information prepared in accordance with GAAP.  In addition, this non-GAAP per share metric may not be the same as non-GAAP per share metrics presented by other companies. Pro forma adjusted EBITDA per share is not a measure of financial performance under GAAP, and is not intended to represent cash flows per share from operations under GAAP and should not be used as an alternative to net income or loss per share as an indicator of operating performance or to represent cash flows from operating, investing or financing activities as a measure of liquidity. Intrexon compensates for the limitations of pro forma adjusted EBITDA per share by using it only to supplement the Company's GAAP results to provide a more complete understanding of the factors and trends affecting the Company's business. Pro forma adjusted EBITDA per share has its limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of Intrexon's results as reported under GAAP.

The following table presents a reconciliation of net income (loss) attributable to Intrexon to EBITDA and also to adjusted EBITDA for each of the periods indicated:



Three months ended



Six months ended


June 30,

June 30,




2014




2013




2014




2013





(In thousands)



Net loss attributable to Intrexon


$

(52,043)



$

(5,963)



$

(47,928)



$

(42,274)



Interest expense



25




10




48




24



Income tax (benefit) expense



(283)







23






Depreciation and amortization



1,937




1,805




3,711




3,673





















EBITDA


$

(50,364)



$

(4,148)



$

(44,146)



$

(38,577)



Stock-based compensation expense



6,817




799




10,557




1,195



Contribution of services by shareholder



507




387




977




775



Unrealized (appreciation) depreciation in fair value of equity securities



33,777




(7,734)




11,855




21,635



Gain on previously held equity investment












(7,415)



Equity in net loss of affiliates



1,355







1,891




390



Impact of change in deferred revenue related to upfront and milestone payments



(2,517)




6,192




26,026




10,455





















Adjusted EBITDA


$

(10,425)



$

(4,504)



$

7,160



$

(11,542)























The following table presents the calculation of pro forma adjusted EBITDA per share, basic and diluted, for each of the periods indicated:



Three months ended



Six months ended


June 30,

June 30,




2014




2013




2014




2013





(In thousands, except share and per share data)



Pro forma adjusted EBITDA per share:


















Numerator:


















Adjusted EBITDA


$

(10,425)



$

(4,504)



$

7,160



$

(11,542)





















Denominator (1):


















Pro forma weighted average common shares used in computing pro forma adjusted EBITDA per share, basic



98,892,601




83,140,829




98,113,493




79,510,437



Pro forma weighted average common shares used in computing pro forma adjusted EBITDA per share, diluted



98,892,601




83,140,829




99,941,705




79,510,437



Pro forma adjusted EBITDA per share, basic


$

(0.11)



$

(0.05)



$

0.07



$

(0.15)



Pro forma adjusted EBITDA per share, diluted


$

(0.11)



$

(0.05)



$

0.07



$

(0.15)
























(1)  Pro forma adjusted EBITDA per share, basic and diluted have been calculated for the three and six month periods ended June 30, 2013 after giving effect to (i) the conversion of 112,906,464 shares of Intrexon's preferred stock outstanding on January 1, 2013 into 64,517,977 shares of common stock upon the completion of its initial public offering; (ii) the issuance of 19,047,619 shares of Series F preferred stock issued between January 1, 2013 and April 30, 2013 and the conversion of those shares into 10,884,353 shares of Intrexon's common stock upon the completion of its initial public offering; and (iii) upon the completion of Intrexon's initial public offering the conversion of aggregate cumulative dividends on the Company's preferred stock of $64.8 million into 4,050,161 shares of its common stock, assuming the initial public offering closed on June 30, 2013 at the initial public offering price of $16.00 per share.

 

SOURCE Intrexon Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...
IT organizations are moving to the cloud in hopes to approve efficiency, increase agility and save money. Migrating workloads might seem like a simple task, but what many businesses don’t realize is that application migration criteria differs across organizations, making it difficult for architects to arrive at an accurate TCO number. In his session at 21st Cloud Expo, Joe Kinsella, CTO of CloudHealth Technologies, will offer a systematic approach to understanding the TCO of a cloud application...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
In his session at @ThingsExpo, Sudarshan Krishnamurthi, a Senior Manager, Business Strategy, at Cisco Systems, discussed how IT and operational technology (OT) work together, as opposed to being in separate siloes as once was traditional. Attendees learned how to fully leverage the power of IoT in their organization by bringing the two sides together and bridging the communication gap. He also looked at what good leadership must entail in order to accomplish this, and how IT managers can be the ...
With Cloud Foundry you can easily deploy and use apps utilizing websocket technology, but not everybody realizes that scaling them out is not that trivial. In his session at 21st Cloud Expo, Roman Swoszowski, CTO and VP, Cloud Foundry Services, at Grape Up, will show you an example of how to deal with this issue. He will demonstrate a cloud-native Spring Boot app running in Cloud Foundry and communicating with clients over websocket protocol that can be easily scaled horizontally and coordinate...
In his session at 20th Cloud Expo, Chris Carter, CEO of Approyo, discussed the basic set up and solution for an SAP solution in the cloud and what it means to the viability of your company. Chris Carter is CEO of Approyo. He works with business around the globe, to assist them in their journey to the usage of Big Data in the forms of Hadoop (Cloudera and Hortonwork's) and SAP HANA. At Approyo, we support firms who are looking for knowledge to grow through current business process, where even 1%...
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
SYS-CON Events announced today that Secure Channels, a cybersecurity firm, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Secure Channels, Inc. offers several products and solutions to its many clients, helping them protect critical data from being compromised and access to computer networks from the unauthorized. The company develops comprehensive data encryption security strategie...
"DX encompasses the continuing technology revolution, and is addressing society's most important issues throughout the entire $78 trillion 21st-century global economy," said Roger Strukhoff, Conference Chair. "DX World Expo has organized these issues along 10 tracks with more than 150 of the world's top speakers coming to Istanbul to help change the world."
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyer belt between the Software Factory and production stages. Artifacts are m...
Vulnerability management is vital for large companies that need to secure containers across thousands of hosts, but many struggle to understand how exposed they are when they discover a new high security vulnerability. In his session at 21st Cloud Expo, John Morello, CTO of Twistlock, will address this pressing concern by introducing the concept of the “Vulnerability Risk Tree API,” which brings all the data together in a simple REST endpoint, allowing companies to easily grasp the severity of t...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
Cloud resources, although available in abundance, are inherently volatile. For transactional computing, like ERP and most enterprise software, this is a challenge as transactional integrity and data fidelity is paramount – making it a challenge to create cloud native applications while relying on RDBMS. In his session at 21st Cloud Expo, Claus Jepsen, Chief Architect and Head of Innovation Labs at Unit4, will explore that in order to create distributed and scalable solutions ensuring high availa...
Connecting to major cloud service providers is becoming central to doing business. But your cloud provider’s performance is only as good as your connectivity solution. Massive Networks will place you in the driver's seat by exposing how you can extend your LAN from any location to include any cloud platform through an advanced high-performance connection that is secure and dedicated to your business-critical data. In his session at 21st Cloud Expo, Paul Mako, CEO & CIO of Massive Networks, wil...